caa a22 4500 465790038 CHVBK 20180323112021.0 cr unu---uuuuu 170327e19900501xx s 000 0 eng 10.1007/BF00177259 doi (NATIONALLICENCE)springer-10.1007/BF00177259 Phase II study of Fludarabine Phosphate in multiple myeloma [Elektronische Daten] A Southwest Oncology Group study [Eric Kraut, John Crowley, Michael Grever, Michael Keppen, John Bonnet, Henry Hynes, Sydney Salmon] Summary: Thirty-one patients with multiple myeloma refractory to therapy or relapsing after response to initial therapy were treated with Fludarabine Phosphate utilizing a daily intravenous schedule for five consecutive days. There were no objective responses seen and only one patient showed clinical improvement. Myelosuppression manifest as leucopenia and granulocytopenia was the primary toxicity seen. Fludarabine Phosphate is inactive in previously treated myeloma patients when given by the daily intravenous route. Kluwer Academic Publishers, 1990 Fludarabine Phosphate nationallicence multiple myeloma nationallicence Kraut Eric Ohio State University, USA aut Crowley John Southwest Oncology Group Statistical Center, Seattle, USA aut Grever Michael Ohio State University, USA aut Keppen Michael University of Arkansas for Medical Science, USA aut Bonnet John Scott & White Clinic, USA aut Hynes Henry Wichita CCOP, USA aut Salmon Sydney University of Arizona Cancer Center, USA aut Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 199-200 0167-6997 8:2<199 1990 8 10637 https://doi.org/10.1007/BF00177259 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00177259 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Kraut Eric Ohio State University, USA aut NATIONALLICENCE 700 1- Crowley John Southwest Oncology Group Statistical Center, Seattle, USA aut NATIONALLICENCE 700 1- Grever Michael Ohio State University, USA aut NATIONALLICENCE 700 1- Keppen Michael University of Arkansas for Medical Science, USA aut NATIONALLICENCE 700 1- Bonnet John Scott & White Clinic, USA aut NATIONALLICENCE 700 1- Hynes Henry Wichita CCOP, USA aut NATIONALLICENCE 700 1- Salmon Sydney University of Arizona Cancer Center, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/2(1990-05-01), 199-200 0167-6997 8:2<199 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer